Impact of Online Tumor Board Simulation for Optimizing Testing and Treatment of Patients with BRAFV600E- mutant Metastatic Colorectal Cancer

Abstract

Abstract Introduction/Objective Approximately 10% of patients with metastatic colorectal cancer (mCRC) have BRAF genetic mutations, 90% of which result in a V600E substitution. Although there are targeted therapies available, there has been confusion about new and emerging testing and treatment options for BRAFV600E-mutant mCRC. Methods/Case Report To meet these needs, ASCP designed a 60-minute, self-paced, CME/CMLE online tumor board simulation to: increase knowledge, skills, and competence of pathologists and laboratory professionals to ensure patients with mCRC are appropriately and efficiently tested for BRAF mutations in accordance with NCCN guidelines, and enable pathologists to guide medical oncologists in the appropriate diagnosis, testing, and treatment of patients with mCRC. In the simulation, an expert pathologist and oncologist presented patient cases involving BRAFV600E-mutant mCRC. Learners answered questions designed to help them carefully consider the nuances of each case, building their knowledge and skills related to the detection and optimal management of patients with BRAF-mutant mCRC. Results (if a Case Study enter NA) 250+ learners have participated, with results demonstrating greater understanding of the NCCN guidelines for molecular testing of patients with mCRC, the clinicopathologic characteristics of BRAF-mutant mCRC. The tumor board simulation also increased awareness of strategies for improving turnaround times in biomarker testing for patients with mCRC, as well as current and emerging treatment options for BRAFV600E-mutant mCRC, which were two of the main goals of the education. Conclusion This project advanced knowledge, skills, and competence among pathologists and laboratory professionals, particularly those in community practice, to help ensure that patients who may be eligible for new and emerging therapies for BRAFV600E-mutant mCRC receive effective, optimized, and timely biomarker testing and treatment. The education may be useful to learners who want an increased understanding of BRAF mutations and their role in treatment selection.